Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs
Most everybody at the high end of the drug R&D business has more trial work on the table than they can afford to complete alone. And that’s where the right development partner can make a big difference.
For Merck KGaA, Pfizer has been shouldering much of the load to advance their PD-L1 checkpoint Bavencio, now in multiple studies for various cancers as it continues to chase a crowded field of players. And the same approach could work elsewhere.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.